Trial Information
Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia
OBJECTIVES:
- To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in
patients with Down syndrome through whole-genome sequencing.
OUTLINE: This is a multicenter study.
Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene
mutation, and microarray analysis.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic
syndromes (MDS)
- Clinical samples from patients enrolled on the Children's Oncology Group (COG)
AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell
Bank
- Diagnostic blast samples and matched remission samples
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Identification of unique mutations through whole-genome sequencing
Safety Issue:
No
Principal Investigator
Jeffrey Taub, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Children's Hospital of Michigan
Authority:
United States: Federal Government
Study ID:
CDR0000721624
NCT ID:
NCT01507441
Start Date:
February 2012
Completion Date:
Related Keywords:
- Leukemia
- childhood myelodysplastic syndromes
- childhood acute myeloid leukemia/other myeloid malignancies
- childhood acute megakaryocytic leukemia (M7)
- Down Syndrome
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid